In the last five weeks there have been 11 very pos

In the last five weeks there have been 11 very positive PRs released documenting SCRC's climb to success. That's an average of 2 a week. The conference call yesterday was the icing on the cake announcing profitability, cash in the bank, continued revenue growth, imminent news on a bank financing deal and finally, the continued excitement for a RapiMeds launch in the Asian market. How many penny stocks can claim this type of activity? I fully expect increased buying from new investors each day. How can anyone look at this stock and not see it as an opportunity for huge financial gains?

Recent News Headlines for ScripsAmerica Inc
ScripsAmerica's Specialty Pharmacy Records Over $5 Million in Approved Orders for the Third Consecutive MonthWednesday 12/03/2014 08:00 AM ET - MarketWire via Dow Jones News
ScripsAmerica's Specialty Pharmacy Records Over $5 Million in Approved Orders for the Third Consecutive Month TYSONS CORNER, VA--(Marketwired - Dec 3, 2014) - ScripsAmerica, Inc. (OTCBB: SCRC) today announced that its wholly owned subsidiary, Main Avenue Pharmacy, reported $5,257,753 in approved orders during November of 2014. This represents the third consecutive month that ScripsAmerica's specialty pharmacy generated over $5 million in sales.

WSA Speaks to Three Companies on the RiseTuesday 12/02/2014 11:27 AM ET - MarketWire via Dow Jones News
WSA Speaks to Three Companies on the Rise Wall Street Analyzer's CEO Interview Series NEW YORK, NY--(Marketwired - December 02, 2014) - ClearOne (NASDAQ: CLRO) CEO Zee Hakimoglu discussed the company's favorable Q3 results reporting 27% revenue growth from last year with solid profitability. She outlined ClearOne's products and patents and talked about two recent acquisitions and how these acquisitions have positioned ClearOne favorably in their traditional audio conferencing market as well as in the emerging media collaboration market.

( SCRC ) SeeThruEquity Initiates Research Coverage on ScripsAmerica with a Price Target of $1.20Tuesday 12/02/2014 09:01 AM ET - Dow Jones News
New York, NY / ACCESSWIRE / December 2, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on ScripsAmerica, Inc. (OTCQB: SCRC) with a 12-month price target of $1.20.

ScripsAmerica Exercises Option to Acquire 90% of PIMD International, LLCMonday 12/01/2014 08:00 AM ET - MarketWire via Dow Jones News
ScripsAmerica Exercises Option To Acquire 90% Of PIMD International, LLC >SCRCMonday 12/01/2014 08:00 AM ET - Dow Jones News
Dow Jones News has only provided a headline at this time.

ScripsAmerica Highlights CEO Interviews From Recent Investor ConferenceTuesday 11/25/2014 08:00 AM ET - MarketWire via Dow Jones News
ScripsAmerica Comments on Financial Results for the Third Quarter of 2014Wednesday 11/19/2014 08:00 AM ET - MarketWire via Dow Jones News
ScripsAmerica Announces Full Acquisition of Main Avenue PharmacyTuesday 11/18/2014 08:00 AM ET - MarketWire via Dow Jones News
ScripsAmerica Announces Full Acquisition Of Main Avenue Pharmacy >SCRCTuesday 11/18/2014 08:00 AM ET - Dow Jones News
Dow Jones News has only provided a headline at this time.

ScripsAmerica Announces Conference Call to Provide Business Update and Discuss Third Quarter Fiscal 2014 ResultsMonday 11/17/2014 08:00 AM ET - BusinessWire via Dow Jones News
"New To The Street" Is Back on the StreetThursday 11/13/2014 01:39 PM ET - MarketWire via Dow Jones News
Small Cap Traders Provides Brief Report on 11/04/2014 04:03 PM ET - Dow Jones News
ScripsAmerica Reports $5.6 Million in Approved Orders for Its Specialty Pharmacy in OctoberTuesday 11/04/2014 08:00 AM ET - MarketWire via Dow Jones News